
    
      This is a Phase 1, non-randomized, open label, single-dose study to evaluate the effect of
      varying degrees of impaired renal function (i.e., mild, moderate, severe Renal Impairment
      (RI), and End-Stage Renal Disease (ESRD) on hemodialysis) on the PK, safety, and tolerability
      of linzagolix and its major metabolite, KP017.

      Up to 40 adult female participants will be enrolled.
    
  